Details for New Drug Application (NDA): 072646
✉ Email this page to a colleague
NDA 072646 describes SILPHEN, which is a drug marketed by Lannett Co Inc and is included in one NDA. Additional details are available on the SILPHEN profile page.
The generic ingredient in SILPHEN is diphenhydramine hydrochloride. There are twenty-three drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the diphenhydramine hydrochloride profile page.
The generic ingredient in SILPHEN is diphenhydramine hydrochloride. There are twenty-three drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the diphenhydramine hydrochloride profile page.
Summary for 072646
| Tradename: | SILPHEN |
| Applicant: | Lannett Co Inc |
| Ingredient: | diphenhydramine hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 072646
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYRUP;ORAL | Strength | 12.5MG/5ML | ||||
| Approval Date: | Feb 27, 1992 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
